Ac3IV

Ac3IV is an enzymatically stable analogue of vasopressin that selectively activates the vasopressin receptors Avpr1a (V1a) and Avpr1b (V1b). It has been studied primarily for its effects on pancreatic islet cell morphology and function in diabetic models. In preclinical studies using streptozotocin-induced diabetic mice, Ac3IV administration improved pancreatic insulin levels, enhanced beta-cell proliferation, reduced beta-cell apoptosis, and partially reversed detrimental changes in islet architecture. It also promoted transdifferentiation between alpha- and beta-cells within the pancreas, helping to preserve beta-cell identity. Despite these benefits on islet structure and cell turnover, blood glucose levels were not significantly changed in severe diabetes models. The drug shows potential for modulating endocrine pancreas function via V1a and V1b receptor activation.